Famciclovir Tablets (Famciclovir)

Adult dose

1. Treatment of herpes zoster Adults: Administer 250 mg of famciclovir orally 3 times daily for 7 days. It is preferable to start treatment as soon as symptoms appear after infection. 2. Treatment of an initial episode of genital herpes Adults: Administer 250 mg of this medicine orally 3 times daily for 5 days. It is preferable to start treatment as soon as symptoms appear after infection. 3. Treatment of acute recurrent genital herpes Adults: Administer 125 mg of this medicine orally twice daily for 5 days. It is preferable to start treatment during the prodromal period or as soon as symptoms appear after infection. 4. Suppression of recurrent genital herpes Adults: Administer 250 mg of this medicine orally twice daily. Discontinue treatment periodically every 6～12 months to assess whether the natural course of the disease has changed. 5. Patients with renal impairment: Because creatinine clearance of this medicine is reduced in patients with renal impairment, adjust the dose with caution. The dosage for these patients is as follows. 1) Treatment of herpes zoster and an initial episode of genital herpes: Creatinine clearance (mL/min/1.73㎡) 30～59: 250 mg per dose twice daily 10～29: 250 mg per dose once daily 2) Treatment of acute recurrent genital herpes: Creatinine clearance (mL/min/1.73㎡) 30～59: 125 mg per dose twice daily 10～29: 125 mg per dose once daily 3) Suppression of recurrent genital herpes: Creatinine clearance (mL/min/1.73㎡) 30～59: 250 mg per dose twice daily 10～29: 125 mg per dose twice daily 4) If only serum creatinine is known, creatinine clearance can be calculated using the following formula. Men: {body weight (kg) × (140-age)}/ {72 × serum creatinine (mg/dL)} Women: 0.85 × the value calculated for men 5) Patients with renal impairment undergoing hemodialysis For patients on hemodialysis, it is preferable to administer this medicine every 48 hours, taking the dialysis interval into account. A 4-hour hemodialysis session reduces the plasma concentration of this medicine by approximately 75%; therefore, administer this medicine immediately after dialysis. The recommended dose is 250mg for patients with herpes zoster and 125mg for patients with genital herpes. 6. Patients with hepatic impairment: No dose adjustment is necessary for patients with chronic compensated liver disease. There is insufficient treatment experience in patients with overt chronic decompensated liver disease; therefore, no clear recommended dose has been established.

This medicine should not be used in certain patients. It should not be administered to patients who have a history of allergy or hypersensitivity to this drug or its active ingredients. Additionally, since this medication contains lactose, it should not be taken by patients with a genetic disorder that impairs lactose digestion. Patients who are allergic to soybean oil or have hypersensitivity to soybeans or peanuts should not use this medication. Patients with impaired kidney function or with abnormalities in lipid metabolism, as well as those who need to use lipid emulsions cautiously, should take this medicine with care. When taking this medicine, gastrointestinal symptoms such as headache, nausea, vomiting, abdominal pain, and diarrhea can occur frequently. Rarely, side effects such as thrombocytopenia or leukopenia, dizziness, confusion, drowsiness, hallucinations, palpitations, liver function abnormalities, skin rashes, angioedema, and acute renal failure have been reported. In particular, elderly patients may experience drowsiness or confusion more readily, so caution is needed. This drug does not cure genital herpes, and it is important to avoid sexual contact when symptoms are present during treatment. Safe sex methods are recommended, and prompt treatment is needed when recurrences occur. This medication typically does not affect driving or operating machinery, but one should refrain from driving or engaging in hazardous tasks if dizziness or drowsiness occurs. Patients with slightly impaired liver function do not require special dose adjustments; however, caution is advised for patients with severe liver impairment as the efficacy may diminish. Patients at risk of complications due to excessive fat should regularly check serum lipid levels and adjust doses as needed. This medication has relatively few interactions with other drugs, but when used in conjunction with certain medications, changes in blood concentration or decreased efficacy may occur, so consultation with a specialist is necessary. Women who are pregnant or may become pregnant should be cautious when taking this medication, and those who are breastfeeding should also discuss use with their physician. Children under 18 years of age should ideally not use this medication as safety and efficacy have not been established. Elderly patients generally do not require dose adjustments, but those with decreased kidney function should adjust doses as necessary. In case of overdose, seek medical attention immediately for appropriate treatment. Hemodialysis can lower the concentration of the active ingredient in this medication. Store this medicine in a sealed container, in a dry place at temperatures below 30 degrees Celsius, away from moisture and out of reach of children, and avoid transferring it to other containers.

• headache
• nausea
• thrombocytopenia
• leukopenia
• neutropenia
• dizziness
• confusion
• drowsiness
• hallucinations
• palpitations

This medication is sensitive to air and moisture, so it should be stored in a sealed container. Additionally, it should be stored in a dry place at temperatures below 30 degrees Celsius to maintain its efficacy.

Appearance

White, round, film-coated tablet

Package unit

21 tablets (3 blister packs of 7 tablets each)